Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126401063 | 12640106 | 3 | F | 2016 | 20160912 | 20160810 | 20160926 | EXP | US-ACORDA-ACO_125780_2016 | ACORDA | 52.87 | YR | F | Y | 0.00000 | 20160926 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126401063 | 12640106 | 1 | PS | AMPYRA | DALFAMPRIDINE | 1 | Oral | 10 MG, Q 12 HRS | 0000079857 | 22250 | 10 | MG | TABLET | Q12H |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126401063 | 12640106 | 1 | Multiple sclerosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126401063 | 12640106 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126401063 | 12640106 | Drug ineffective | |
| 126401063 | 12640106 | Drug ineffective for unapproved indication | |
| 126401063 | 12640106 | Fall | |
| 126401063 | 12640106 | Joint lock | |
| 126401063 | 12640106 | Lung carcinoma cell type unspecified stage I | |
| 126401063 | 12640106 | Multiple sclerosis relapse | |
| 126401063 | 12640106 | Paraneoplastic syndrome | |
| 126401063 | 12640106 | Temperature intolerance |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126401063 | 12640106 | 1 | 20160522 | 0 |